Research Publications
The latest from Maverex.
Latest Posts
Find our peer-reviewed research publications across oncology, cardiovascular, infectious disease and much more.
Therapeutic benefit of orphan drugs in oncology: evidence at the point of European Marketing Authorisation
Odnoletkova I, Marjenberg Z, Pooley N, Langham S. Therapeutic benefit of orphan drugs in oncology: evidence at the point of European Marketing Authorisation. Value Health 2019;22(Suppl 3): S491
The patient perspective in health technology assessment reimbursement decisions for orphan drugs across different countries
Nicholson L, Langham S, Adkins E. The patient perspective in health technology assessment reimbursement decisions for orphan drugs across different countries. Value Health 2019:22(Suppl 3):S860
A systematic review of single-inhaler triple therapy in patients with chronic obstructive pulmonary disease (COPD)
Langham S, Lewis J, Pooley N, Embleton N, Langham J. A systematic review of single-inhaler triple therapy in patients with chronic obstructive pulmonary disease (COPD). Value Health 2019;22(Suppl 3):S873
Transparency in decision modelling: what, why, who and how?
Sampson CJ, Arnold R, Bryan S, Clarke P, Ekins S, Hatswell A, Hawkins N, Langham S, Marshall D, Sadatsafavi M, Sullivan W, Wilson ECF, Wrightson T. Transparency in decision modelling: what, why, who and how? Pharmacoeconomics 2019;37(11):1355–69
Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review
Langham S, Lewis J, Pooley N, Embleton N, Langham J, Han MK, Chalmers JD. Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic and descriptive review. Respir Res 2019;20(1):242
Budget impact analysis of methoxyflurane (Penthrox®) for emergency relief of moderate-to-severe trauma pain in the Swedish setting
Kenworthy J, Langham S, Wright A, Dunlop W. Budget impact analysis of methoxyflurane (Penthrox®) for emergency relief of moderate-to-severe trauma pain in the Swedish setting. Value Health 2018;21(Suppl 3):S443
Choosing the right software for HTA economic models: a comparison of four programmes recommended by the National Institute for Health and Care Excellence
Wright A, Embleton N, Langham S. Choosing the right software for HTA economic models: a comparison of four programmes recommended by the National Institute for Health and Care Excellence. Value Health 2018;21(Suppl 3):S380
Cost-Effectiveness of Take-Home Naloxone for the Prevention of Overdose Fatalities among Heroin Users in the United Kingdom
Langham S, Wright A, Kenworthy J, Grieve R, Dunlop WCN. Cost-effectiveness of take-home naloxone for the prevention of overdose fatalities among heroin users in the UK. Value Health 2018;21(4):407–15. Open access ‘R’ and ‘Excel model’
Health technology assessment of companion diagnostics alongside therapeutic agents in oncology: experience of the NICE technology appraisal programme
Langham S, Lewis J. Health technology assessment of companion diagnostics alongside therapeutic agents in oncology: experience of the NICE technology appraisal programme. Value Health 2018;21(Suppl 3):S272
